Background: Low-flow, low-gradient aortic stenosis with reduced left ventricular ejection fraction is a heterogeneous condition with challenging severity assessment. Aortic valve calcification reflects fibro-calcific remodeling, while oxidative stress plays a key role in its pathogenesis. Serum uric acid, a marker of oxidative stress, may be associated with valvular calcification. This study investigated the relationship between serum uric acid levels and aortic valve calcification in this population. Methods: This retrospective study included 85 patients. Aortic valve calcification was quantified using computed tomography with the Agatston method, and patients were categorized as true severe or pseudo-severe according to sex-specific calcium thresholds. Of the patients, 57 were classified as true severe and 28 as pseudo-severe aortic stenosis. Results: Patients with higher calcification burden had significantly elevated serum uric acid levels (6.77 ± 1.57 vs. 5.08 ± 1.10 mg/dL, p < 0.001). Serum uric acid showed a modest correlation with aortic valve calcium score (ρ = 0.339, p = 0.002) and remained independently associated with CT-defined true severe low-flow, low-gradient aortic stenosis in multivariable analysis. ROC analysis yielded an area under the curve of 0.823 and identified a serum uric acid threshold of 5.45 mg/dL associated with a greater likelihood of CT-defined true severe low-flow, low-gradient aortic stenosis. Conclusions: Serum uric acid is associated with CT-derived aortic valve calcification and may provide insight into underlying fibro-calcific remodeling in this population.
27 March 2025 in Journal of Cardiology & Cardiovascular Surgery
Aims: Functional mitral regurgitation (FMR) is an important condition associated with advanced heart failure and poor prognosis. The aim of this study was to investigate the effects of diastolic (presystolic) tricuspid regurgitation (DTR) on right ventricular function, survival rates and functional capacity in patients with advanced FMR. The relationship between DTR and right ventricular systolic function and the predictive factors involved in its development were also evaluated. Methods: The study included 64 patients with advanced FMR who were evaluated for mitraclip therapy between June 2014 and February 2015. Demographic characteristics, cardiovascular risk factors, New York Heart Association (NYHA) functional classification and laboratory data were recorded. Left and right ventricular parameters were examined by echocardiography, and the diagnosis of DTR was made by color Doppler method. Estimated survival rates were evaluated using the Seattle Heart Failure Model Score (SHFSM) with 1- and 5-year projections. Results: DTR was detected in 14 (22%) of the patients included in the study. The majority (85.7%) of the patients in the group with DTR were in NYHA III-IV stage and had low functional capacity. DTR showed significant assocation with right ventricular fractional area change (RV FAC), right ventricular peak systolic myocardial velocity (RV Sm), TAPSE, tricuspid regurgitation, ejection fraction, pulmonary artery systolic pressure, and pulmonary vascular resistance (p<0.05). In addition, DTR group had lower estimated survival rates compared to SHFSM (1-year estimated survival 64%, 5-year estimated survival 35%; p<0.001). In Binary Logistic Regression Analysis, RV FAC and RV Sm values were found to be independent predictors for the development of DTR. Conclusion: DTR is an important echocardiographic parameter that indicates poor prognosis in patients with advanced FMR. This study demonstrated that DTR is associated with right ventricular dysfunction and decreased estimated survival rates. Early diagnosis of DTR may provide an important contribution to clinical management and prognostic evaluation in this patient group.
22 January 2026 in Clinical and Experimental Hypertension
Renal denervation (RDN) has emerged as a potential therapeutic option for resistant hypertension (HT), which remains a major clinical challenge due to poor blood pressure (BP) control despite optimized pharmacotherapy. This study aimed to assess the safety and effectiveness of catheter-based RDN in resistant hypertension patients, based on our center's experience. This retrospective, single-center study included 120 patients with resistant HT who were eligible for RDN and underwent the procedure using the Symplicity Spyral system between January 2023 and December 2024. Office systolic and diastolic BP were assessed at baseline and 6 months after RDN. The primary endpoint was the reduction in BP, while secondary endpoints included changes in the number of antihypertensive medications. At 6 months, office systolic BP decreased significantly from 156 ± 7.7 mmHg to 143 ± 3.7 mmHg, while diastolic BP declined from 93.5 ± 5.5 mmHg to 90 ± 3.9 mmHg (both p < 0.001). Median per-patient reductions were 13 mmHg systolic and 3.5 mmHg diastolic. The mean number of antihypertensive medications decreased from 4.88 ± 0.9 to 4.47 ± 1.1 (p < 0.001). Minor adverse events included acute kidney injury in two patients (1.7%) and femoral artery injury in one patient (0.8%). Catheter-based RDN using the Symplicity Spyral system was safe and effective in reducing BP and medication burden in patients with resistant HT. These results support RDN as a potential therapeutic option in appropriately selected patients.
Objectives: Inflammation plays a very important role in the pathogenesis of coronary artery disease (CAD) and its prognosis. Especially; C-reactive protein (CRP) is associated with poor prognosis in patients with CAD. In this study, the relationship between CRP levels and body mass ındex (BMI) was investigated in patients who underwent primary coronary intervention (PCI) due to ST elevation myocardial infarction (STEMI). Methods: Between January 2015 and February 2016, 132 patients who underwent PCI due to acute STEMI were included in the retrospective study. Patients were classified into two groups: (Group 1: BMI 35 kg/m2 n=9, total: 36 patients; Group 2: 25 <BMI <30 kg/m2 n=58 and 30 <BMI BMI <35. Whereas, it was significantly higher in STEMI patients with 25 35. One of the reasons for the better prognosis of mildly overweight and Class 1 obese patients with STEMI diagnosis may be the low values of CRP which has many effects on atherosclerotic plaque formation.